Targeted Therapies in Neurofibromatosis Type 1
American Journal of Medical Genetics Part C: Seminars in Medical Genetics · 2025-09 · 199 (3) · 154-160
DOI: 10.1002/ajmg.c.32151 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Medical Genetics Part C: Seminars in Medical Genetics, online erschienen am 18.09.2025. Verfasst von Aimee A Sato und 2 weiteren Autor:innen. Beteiligte Einrichtung: University of Washington, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Neurofibromatosis 1, Molecular Targeted Therapy, Protein Kinase Inhibitors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 54 Literaturangaben.
Abstract (Originalsprache)
Neurofibromatosis type 1 (NF1) is a progressive multisystem condition that is characterized by a wide range of clinical manifestations and clinical variability. Individuals with NF1 can be significantly impacted by NF1‐related complications, and targeted therapies are emerging. Currently, MEK inhibitors selumetinib and mirdametinib are the only FDA‐approved targeted therapies for NF1‐related symptomatic or progressive, inoperable plexiform neurofibromas. Several additional MEK inhibitors are being investigated in clinical trials for the treatment of plexiform neurofibromas. Additional therapies are currently under investigation for the treatment of malignant peripheral nerve sheath tumors, low‐grade gliomas, skeletal manifestations, cutaneous neurofibromas, and other NF1‐related complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Washington, Seattle, Washington, USA.
- Division of Genetic Medicine, University of Washington (SEW), Seattle Children's Hospital (DE), Seattle, Washington, USA.
ORCID-Profile: Aimee A Sato, Dawn Earl, Stephanie E Wallace
Zitieren
APA
Sato, A. A., Earl, D., & Wallace, S. E. (2025). Targeted Therapies in Neurofibromatosis Type 1. American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 199(3), 154-160. https://doi.org/10.1002/ajmg.c.32151
Vancouver
Sato AA, Earl D, Wallace SE. Targeted Therapies in Neurofibromatosis Type 1. American Journal of Medical Genetics Part C: Seminars in Medical Genetics. 2025;199(3):154-160. doi:10.1002/ajmg.c.32151
BibTeX
@article{Sato2025,
author = {Sato, Aimee A and Earl, Dawn and Wallace, Stephanie E},
title = {Targeted Therapies in Neurofibromatosis Type 1},
journal = {American Journal of Medical Genetics Part C: Seminars in Medical Genetics},
year = {2025},
volume = {199},
number = {3},
pages = {154--160},
doi = {10.1002/ajmg.c.32151}
}
EUVIMED